Longeveron (LGVN) Investor presentation summary

Strategic leadership and corporate repositioning

• New CEO Steve Willard appointed in February 2026, bringing experience in billion-dollar valuations and major licensing deals.

• Shift to a capital-light model, prioritizing HLHS Phase 2b data readout in August 2026 to extend operating runway.

• Focus on high-value global licensing opportunities for laromestrocel (Lomecel-BⓇ) across four indications.

• Completed up to $30M financing in March 2026, led by Coastlands Capital and Janus Henderson.

• Strong scientific leadership and robust IP portfolio with 50+ issued and 60+ pending patents.

Clinical pipeline and lead programs

• Laromestrocel targets HLHS, PDCM, Alzheimer's Disease, and Aging-related Frailty, each with significant unmet medical needs.

• HLHS Phase 2b trial (ELPIS II) fully enrolled; top-line 12-month data expected August 2026.

• Phase 1 HLHS trial showed 100% transplant-free survival at 5 years, compared to 80% in historical controls.

• PDCM program has FDA-approved IND for a single Phase 2 registration study, targeting a $1B+ global market.

• Alzheimer's program completed Phase 2a with positive brain volume and cognitive data; only cellular therapy with FDA RMAT designation for AD.

Market opportunity and regulatory assets

• HLHS and PDCM each represent ~$1B annual market opportunity; AD and Aging-related Frailty represent $5B+ and $4B+ markets, respectively.

• HLHS program may be eligible for a Priority Review Voucher (PRV) upon BLA approval, valued at $150–$200M based on recent sales.

• Five FDA expedited designations across pipeline: RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease.

• IP portfolio and regulatory exclusivity provide up to 12 years of market protection post-approval.